fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): PMS-Eletriptan (02434342), PMS-Eletriptan (02434350). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Eletriptan

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Apo-Eletriptan Tablets · DIN 02518015 · 20 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Eletriptan Tablets · DIN 02518015 Manufacturer: Apotex Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-06-01 · brand APO-ELETRIPTAN TABLETS · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02518015)

Source record
DIN 02518015: Apo-Eletriptan Tablets Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200049; group id 537; item number 1454; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02518015 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100735
Interchangeable products
Apo-Eletriptan · DIN 02386054 · not recorded Auro-Eletriptan · DIN 02479451 · not recorded Eletriptan · DIN 02511266 · not recorded Gd-Eletriptan · DIN 02342235 · not recorded Jamp Eletriptan · DIN 02493683 · not recorded Relpax · DIN 02256290 · not recorded Teva-Eletriptan · DIN 02382091 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02518015
Shortage record checked October 6, 2026

Auro-Eletriptan · DIN 02479451 · 20 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Auro-Eletriptan · DIN 02479451 Manufacturer: Auro Pharma Inc.; listing date 2019-04-30 Health Canada: Marketed since 2019-02-01 · brand AURO-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02479451)

Source record
DIN 02479451: Auro-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200049; group id 537; item number 1454; lccId None; manufacturer id AUR Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02479451 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97013
Interchangeable products
Apo-Eletriptan · DIN 02386054 · not recorded Apo-Eletriptan Tablets · DIN 02518015 · not recorded Eletriptan · DIN 02511266 · not recorded Gd-Eletriptan · DIN 02342235 · not recorded Jamp Eletriptan · DIN 02493683 · not recorded Relpax · DIN 02256290 · not recorded Teva-Eletriptan · DIN 02382091 · not recorded
Shortage status: resolved shortage (ended December 13, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479451
Shortage record checked October 6, 2026

Eletriptan · DIN 02511266 · 20 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Eletriptan · DIN 02511266 Manufacturer: Sanis Health Inc.; listing date 2021-06-30 Health Canada: Marketed since 2021-07-22 · brand ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02511266)

Source record
DIN 02511266: Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200049; group id 537; item number 1454; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02511266 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100048
Interchangeable products
Apo-Eletriptan · DIN 02386054 · not recorded Apo-Eletriptan Tablets · DIN 02518015 · not recorded Auro-Eletriptan · DIN 02479451 · not recorded Gd-Eletriptan · DIN 02342235 · not recorded Jamp Eletriptan · DIN 02493683 · not recorded Relpax · DIN 02256290 · not recorded Teva-Eletriptan · DIN 02382091 · not recorded
Shortage status: resolved shortage (ended May 13, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02511266
Shortage record checked October 6, 2026

Gd-Eletriptan · DIN 02342235 · 20 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Gd-Eletriptan · DIN 02342235 Manufacturer: Upjohn Canada ULC; listing date 2013-01-29 Health Canada: Marketed since 2026-07-16 · brand VTRS-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02342235)

Source record
DIN 02342235: Gd-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200049; group id 537; item number 1454; lccId None; manufacturer id UJC Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02342235 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82774
Interchangeable products
Apo-Eletriptan · DIN 02386054 · not recorded Apo-Eletriptan Tablets · DIN 02518015 · not recorded Auro-Eletriptan · DIN 02479451 · not recorded Eletriptan · DIN 02511266 · not recorded Jamp Eletriptan · DIN 02493683 · not recorded Relpax · DIN 02256290 · not recorded Teva-Eletriptan · DIN 02382091 · not recorded
Shortage status: active shortage (reported June 1, 2026, estimated to end November 10, 2026, last updated September 9, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02342235
Shortage record checked October 6, 2026

Jamp Eletriptan · DIN 02493683 · 20 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Jamp Eletriptan · DIN 02493683 Manufacturer: Jamp Pharma Corporation; listing date 2021-07-30 Health Canada: Marketed since 2026-03-31 · brand JAMP ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02493683)

Source record
DIN 02493683: Jamp Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200049; group id 537; item number 1454; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02493683 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98368
Interchangeable products
Apo-Eletriptan · DIN 02386054 · not recorded Apo-Eletriptan Tablets · DIN 02518015 · not recorded Auro-Eletriptan · DIN 02479451 · not recorded Eletriptan · DIN 02511266 · not recorded Gd-Eletriptan · DIN 02342235 · not recorded Relpax · DIN 02256290 · not recorded Teva-Eletriptan · DIN 02382091 · not recorded
Shortage status: resolved shortage (ended March 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02493683
Shortage record checked October 6, 2026

Relpax · DIN 02256290 · 20 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Savings card: RxHelp ONE lists Relpax (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Relpax · DIN 02256290 Manufacturer: Upjohn Canada ULC; listing date 2013-01-29 Health Canada: Marketed since 2023-08-30 · brand RELPAX · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Relpax: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02256290)

Source record
DIN 02256290: Relpax Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200049; group id 537; item number 1454; lccId None; manufacturer id UJC Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02256290 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74152
Interchangeable products
Apo-Eletriptan · DIN 02386054 · not recorded Apo-Eletriptan Tablets · DIN 02518015 · not recorded Auro-Eletriptan · DIN 02479451 · not recorded Eletriptan · DIN 02511266 · not recorded Gd-Eletriptan · DIN 02342235 · not recorded Jamp Eletriptan · DIN 02493683 · not recorded Teva-Eletriptan · DIN 02382091 · not recorded
Shortage status: active shortage (reported May 21, 2026, estimated to end November 10, 2026, last updated September 29, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02256290
Shortage record checked October 6, 2026

Teva-Eletriptan · DIN 02382091 · 20 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Teva-Eletriptan · DIN 02382091 Manufacturer: Teva Canada Limited; listing date 2013-11-28 Health Canada: Marketed since 2013-12-20 · brand TEVA-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02382091)

Source record
DIN 02382091: Teva-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200049; group id 537; item number 1454; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02382091 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86796
Interchangeable products
Apo-Eletriptan · DIN 02386054 · not recorded Apo-Eletriptan Tablets · DIN 02518015 · not recorded Auro-Eletriptan · DIN 02479451 · not recorded Eletriptan · DIN 02511266 · not recorded Gd-Eletriptan · DIN 02342235 · not recorded Jamp Eletriptan · DIN 02493683 · not recorded Relpax · DIN 02256290 · not recorded
Shortage status: resolved shortage (ended April 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02382091
Shortage record checked October 6, 2026

Apo-Eletriptan Tablets · DIN 02518023 · 40 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Eletriptan Tablets · DIN 02518023 Manufacturer: Apotex Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-06-01 · brand APO-ELETRIPTAN TABLETS · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02518023)

Source record
DIN 02518023: Apo-Eletriptan Tablets Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id APX Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02518023 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100736
Interchangeable products
Apo-Eletriptan · DIN 02386062 · not recorded Auro-Eletriptan · DIN 02479478 · not recorded Eletriptan · DIN 02511274 · not recorded Gd-Eletriptan · DIN 02342243 · not recorded Jamp Eletriptan · DIN 02493691 · not recorded Relpax · DIN 02256304 · not recorded Teva-Eletriptan · DIN 02382105 · not recorded
Shortage status: resolved shortage (ended November 21, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02518023
Shortage record checked October 6, 2026

Auro-Eletriptan · DIN 02479478 · 40 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Auro-Eletriptan · DIN 02479478 Manufacturer: Auro Pharma Inc.; listing date 2019-04-30 Health Canada: Marketed since 2019-02-01 · brand AURO-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02479478)

Source record
DIN 02479478: Auro-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id AUR Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02479478 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97014
Interchangeable products
Apo-Eletriptan · DIN 02386062 · not recorded Apo-Eletriptan Tablets · DIN 02518023 · not recorded Eletriptan · DIN 02511274 · not recorded Gd-Eletriptan · DIN 02342243 · not recorded Jamp Eletriptan · DIN 02493691 · not recorded Relpax · DIN 02256304 · not recorded Teva-Eletriptan · DIN 02382105 · not recorded
Shortage status: resolved shortage (ended June 22, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02479478
Shortage record checked October 6, 2026

Eletriptan · DIN 02511274 · 40 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Eletriptan · DIN 02511274 Manufacturer: Sanis Health Inc.; listing date 2021-06-30 Health Canada: Marketed since 2021-07-22 · brand ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02511274)

Source record
DIN 02511274: Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id SAI Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02511274 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100049
Interchangeable products
Apo-Eletriptan · DIN 02386062 · not recorded Apo-Eletriptan Tablets · DIN 02518023 · not recorded Auro-Eletriptan · DIN 02479478 · not recorded Gd-Eletriptan · DIN 02342243 · not recorded Jamp Eletriptan · DIN 02493691 · not recorded Relpax · DIN 02256304 · not recorded Teva-Eletriptan · DIN 02382105 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02511274
Shortage record checked October 6, 2026

Gd-Eletriptan · DIN 02342243 · 40 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Gd-Eletriptan · DIN 02342243 Manufacturer: Upjohn Canada ULC; listing date 2013-01-29 Health Canada: Marketed since 2026-07-16 · brand VTRS-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02342243)

Source record
DIN 02342243: Gd-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id UJC Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02342243 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82775
Interchangeable products
Apo-Eletriptan · DIN 02386062 · not recorded Apo-Eletriptan Tablets · DIN 02518023 · not recorded Auro-Eletriptan · DIN 02479478 · not recorded Eletriptan · DIN 02511274 · not recorded Jamp Eletriptan · DIN 02493691 · not recorded Relpax · DIN 02256304 · not recorded Teva-Eletriptan · DIN 02382105 · not recorded
Shortage status: resolved shortage (ended February 3, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02342243
Shortage record checked October 6, 2026

Jamp Eletriptan · DIN 02493691 · 40 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Jamp Eletriptan · DIN 02493691 Manufacturer: Jamp Pharma Corporation; listing date 2021-07-30 Health Canada: Marketed since 2026-03-31 · brand JAMP ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02493691)

Source record
DIN 02493691: Jamp Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id JPC Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02493691 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98369
Interchangeable products
Apo-Eletriptan · DIN 02386062 · not recorded Apo-Eletriptan Tablets · DIN 02518023 · not recorded Auro-Eletriptan · DIN 02479478 · not recorded Eletriptan · DIN 02511274 · not recorded Gd-Eletriptan · DIN 02342243 · not recorded Relpax · DIN 02256304 · not recorded Teva-Eletriptan · DIN 02382105 · not recorded
Shortage status: resolved shortage (ended March 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02493691
Shortage record checked October 6, 2026

Relpax · DIN 02256304 · 40 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Savings card: RxHelp ONE lists Relpax (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Relpax · DIN 02256304 Manufacturer: Upjohn Canada ULC; listing date 2013-01-29 Health Canada: Marketed since 2023-08-30 · brand RELPAX · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Relpax: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02256304)

Source record
DIN 02256304: Relpax Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id UJC Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02256304 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74153
Interchangeable products
Apo-Eletriptan · DIN 02386062 · not recorded Apo-Eletriptan Tablets · DIN 02518023 · not recorded Auro-Eletriptan · DIN 02479478 · not recorded Eletriptan · DIN 02511274 · not recorded Gd-Eletriptan · DIN 02342243 · not recorded Jamp Eletriptan · DIN 02493691 · not recorded Teva-Eletriptan · DIN 02382105 · not recorded
Shortage status: resolved shortage (ended February 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02256304
Shortage record checked October 6, 2026

Teva-Eletriptan · DIN 02382105 · 40 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Teva-Eletriptan · DIN 02382105 Manufacturer: Teva Canada Limited; listing date 2013-11-28 Health Canada: Marketed since 2013-12-20 · brand TEVA-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02382105)

Source record
DIN 02382105: Teva-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id TEV Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02382105 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86797
Interchangeable products
Apo-Eletriptan · DIN 02386062 · not recorded Apo-Eletriptan Tablets · DIN 02518023 · not recorded Auro-Eletriptan · DIN 02479478 · not recorded Eletriptan · DIN 02511274 · not recorded Gd-Eletriptan · DIN 02342243 · not recorded Jamp Eletriptan · DIN 02493691 · not recorded Relpax · DIN 02256304 · not recorded
Shortage status: resolved shortage (ended February 24, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02382105
Shortage record checked October 6, 2026

Apo-Eletriptan · DIN 02386054 · 20 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since February 6, 2022 · checked October 5, 2026 · What does dormant mean?
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Eletriptan · DIN 02386054 Manufacturer: Apotex Inc.; listing date 2013-05-31 Health Canada: Dormant since 2022-02-06 · brand APO-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 20 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02386054)

Source record
DIN 02386054: Apo-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200049; group id 537; item number 1454; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02386054 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87164
Interchangeable products
Apo-Eletriptan Tablets · DIN 02518015 · not recorded Auro-Eletriptan · DIN 02479451 · not recorded Eletriptan · DIN 02511266 · not recorded Gd-Eletriptan · DIN 02342235 · not recorded Jamp Eletriptan · DIN 02493683 · not recorded Relpax · DIN 02256290 · not recorded Teva-Eletriptan · DIN 02382091 · not recorded
Shortage status: resolved shortage (ended June 1, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386054
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since February 6, 2022 — choose a marketed DIN from the same-category list.

Apo-Eletriptan · DIN 02386062 · 40 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since July 28, 2023 · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Eletriptan · DIN 02386062 Manufacturer: Apotex Inc.; listing date 2013-05-31 Health Canada: Dormant since 2023-07-28 · brand APO-ELETRIPTAN · ATC N02CC06 ELETRIPTAN · form Tablet · route Oral · ingredients ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) 40 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02386062)

Source record
DIN 02386062: Apo-Eletriptan Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 289200050; group id 537; item number 1455; lccId None; manufacturer id APX Source form: Tab; strength: 40mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $10.0850; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02386062 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87165
Interchangeable products
Apo-Eletriptan Tablets · DIN 02518023 · not recorded Auro-Eletriptan · DIN 02479478 · not recorded Eletriptan · DIN 02511274 · not recorded Gd-Eletriptan · DIN 02342243 · not recorded Jamp Eletriptan · DIN 02493691 · not recorded Relpax · DIN 02256304 · not recorded Teva-Eletriptan · DIN 02382105 · not recorded
Shortage status: resolved shortage (ended November 18, 2021); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386062
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 28, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N02CC): coverage varies; not interchangeable

  • Almotriptan (Axert): not a benefit
  • Frovatriptan (Frova): not a benefit
  • Naratriptan (Amerge): not a benefit
  • Rizatriptan (Maxalt RPD): not a benefit
  • Sumatriptan (Imitrex): not a benefit
  • Zolmitriptan (Zomig Rapimelt): not a benefit

1 more in the class list below

Other drugs in the same formulary class (28:92 Miscellaneous Central Nervous System Drugs) and how they are covered

Matched class: 28:92 Miscellaneous Central Nervous System Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PIZOTYLINE Some products covered without a code (check the product listing): ATOMOXETINE HCL, PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 28:92 Miscellaneous Central Nervous System Drugs

ALMOTRIPTAN

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6.25mg, 12.5mg · Tab

FROVATRIPTAN SUCCINATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Tab

NARATRIPTAN HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2.5mg · Tab

RIZATRIPTAN

· 44 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Orally Disintegrating Tab, Tab

SUMATRIPTAN SUCCINATE

· 38 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 6mg/0.5mL, 25mg, 50mg, 100mg · Inj Sol-Pref Syr 0.5mL Pk, Tab

ZOLMITRIPTAN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg · Orally Disintegrating Tab, Tab

PIZOTYLINE

· 1 products · General benefit · strengths: 1mg · Tab

ATOMOXETINE HCL

· 59 products · Listed, not a benefit (5), General benefit (40), Off-Formulary Interchangeable, not an ODB benefit (14) · strengths: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg · Cap

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

· 28 products · General benefit (19), Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2) · strengths: 0.25mg, 0.5mg, 1mg, 1.5mg · Tab

ACAMPROSATE CALCIUM

· 1 products · Limited Use, codes 531 · strengths: 333mg · DR Tab

ENTACAPONE

· 4 products · Limited Use, codes 367 · strengths: 200mg · Tab

DIMETHYL FUMARATE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 120mg, 240mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:92 and 1 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:12 Anticonvulsants, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults RELPAX (eletriptan hydrobromide) is indicated for the acute treatment of migraine with or without aura in adults. RELPAX tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of RELPAX tablets have not been established for cluster headache, which is present in an older, predominantly male population. Pediatrics (< 18 years of age) The safety and efficacy of RELPAX in children has not been established and its use in this age group is not recommended. (See WARNINGS and PRECAUTIONS) Geriatrics (> 65 x years of age) Experience of the use of RELPAX in patients aged over 65 years is limited. Therefore the use of RELPAX in patients over 65 years is not recommended. (See WARNINGS and PRECAUTIONS). https://pdf.hres.ca/dpd_pm/00072295.PDF PM date: not printed or not captured Source product: RELPAX; DIN 02256290; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Gd-Eletriptan · DIN 02342235 Shortage status: active shortage (reported 2026-06-01, estimated to end 2026-11-10, last updated 2026-09-09); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02342235

Check this DIN again

Relpax · DIN 02256290 Shortage status: active shortage (reported 2026-05-21, estimated to end 2026-11-10, last updated 2026-09-29); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02256290

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Apo-Eletriptan Tablets, Auro-Eletriptan, Eletriptan, Gd-Eletriptan, Jamp Eletriptan, Relpax, Teva-Eletriptan, Apo-Eletriptan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026